An internal promoter underlies the difference in disease severity between N- and C-terminal truncation mutations of Titin in zebrafish

Jun Zou(University of California, San Francisco), Diana A. Tran(University of California, San Francisco), Mai Baalbaki(University of California, San Francisco), Ling Tang(University of California, San Francisco), Annie Poon(University of California, San Francisco), Angelo Pelonero(University of California, San Francisco), Erron W. Titus(University of California, San Francisco), Christiana Yuan(University of California, San Francisco), Chenxu Shi(University of California, San Francisco), Shruthi Patchava(University of California, San Francisco), Elizabeth Halper(University of California, San Francisco), Jasmine Garg(University of California, San Francisco), Irina Movsesyan(University of California, San Francisco), Chaoying Yin(University of North Carolina at Chapel Hill), Roland S. Wu(University of California, San Francisco), Lisa D. Wilsbacher(University of California, San Francisco), Jiandong Liu(University of North Carolina at Chapel Hill), Ronald L. Hager(Brigham Young University), Shaun R. Coughlin(University of California, San Francisco), Martin Jínek(University of Zurich), Clive R. Pullinger(University of California, San Francisco), John P. Kane(University of California, San Francisco), Daniel Hart(University of California, San Francisco), Pui–Yan Kwok(University of California, San Francisco), Rahul C. Deo(QB3)
eLife
October 16, 2015
Cited by 108Open Access
Full Text

Abstract

Truncating mutations in the giant sarcomeric protein Titin result in dilated cardiomyopathy and skeletal myopathy. The most severely affected dilated cardiomyopathy patients harbor Titin truncations in the C-terminal two-thirds of the protein, suggesting that mutation position might influence disease mechanism. Using CRISPR/Cas9 technology, we generated six zebrafish lines with Titin truncations in the N-terminal and C-terminal regions. Although all exons were constitutive, C-terminal mutations caused severe myopathy whereas N-terminal mutations demonstrated mild phenotypes. Surprisingly, neither mutation type acted as a dominant negative. Instead, we found a conserved internal promoter at the precise position where divergence in disease severity occurs, with the resulting protein product partially rescuing N-terminal truncations. In addition to its clinical implications, our work may shed light on a long-standing mystery regarding the architecture of the sarcomere.


Related Papers

No related papers found

Powered by citation graph analysis